



Addressing Unmet Needs in Food Allergy: **Recent Advances, Ongoing Challenges, and Prospects for the Future**

December 7-8, 2023 | National Press Club, Washington DC

AGENDA

6:00 PM – 7:00 PM	Cocktail Reception
7:00 PM – 7:15 PM	Welcome & Opening Remarks Sung Poblete, PhD, RN
7:15 PM – 8:15 PM	Keynote: Promoting the Translation of Food Allergy Clinical Research Findings into Useful Therapies <ul style="list-style-type: none">• NIAID Perspective: Alkis Togias, MD• FDA Perspective: Anubha Tripathi, MD
8:15 PM – 8:45 PM	Q&A Panel Discussion Moderator: Aikaterini (Katherine) Anagnostou, MD, PhD
8:45 PM – 9:45 PM	Dessert Reception

Welcome

8:00 AM – 8:25 AM	Continental Breakfast
8:25 AM – 8:30 AM	Welcome & Opening Remarks Stephen Tilles, MD

Session 1: Prevention

8:30 AM – 8:45 AM	Screening Before Early Food Introduction: Yes or No? Marcus Shaker, MD, MSc
8:45 AM – 9:00 AM	Are We Decreasing Food Allergy Incidence and Prevalence with Early Introduction? Ania Nowak-Wegrzyn, MD, PhD
9:00 AM – 9:15 AM	Barriers to Successful Food Allergy Prevention Jonathan Spergel, MD, PhD
9:15 AM – 9:30 AM	Ways to Make Early Introduction Work Sayantani (Tina) Sindher, MD
9:30 AM – 9:55 AM	Q&A Panel Discussion Moderators: Aikaterini (Katherine) Anagnostou, MD, PhD, Stephen Tilles, MD
9:55 AM – 10:10 AM	Break

Session 2: Diagnostics

10:10 AM – 10:25 AM	Traditional Versus New Food Allergy Testing: Which to Use? Matthew Greenhawt, MD
10:25 AM – 10:40 AM	Food Allergy Phenotypes: What Are They and How Do We Identify Them? Jay Lieberman, MD
10:40 AM – 10:55 AM	How to Ensure Optimal Use of Current Food Allergy Diagnostics Hugh Sampson, MD

10:55 AM – 11:20 AM

Q&A | Panel Discussion

Aikaterini (Katherine) Anagnostou, MD, PhD, Sarina Tanimoto, MD, MBA

Session 3: Food Immunotherapy: Is Standardized Food Allergen Required?

11:20 AM – 11:35 AM

Clinician's Perspective

S. Shahzad Mustafa, MD

11:35 AM – 11:50 AM

Manufacturer's Perspective

Michael Holfinger, PhD

11:50 AM – 12:05 AM

Regulator's Perspective

Ronald Rabin, MD

12:05 AM – 12:30 PM

Q&A | Panel Discussion

Moderators: Sarina Tanimoto, MD, MBA, Stephen Tilles, MD

12:30 PM – 12:45 PM

Break and Transition to Working Lunch

Session 4: Treatments in Development

12:45 PM – 1:00 PM

Food OIT, SLIT, EPIT: Available Now or Soon – When and for Whom?

Yamini Virkud, MD, MA, MPH

1:00 PM – 1:15 PM

Biologics for Food Allergy: What Does the Future Hold?

Daniel Adelman, MD

1:15 PM – 1:30 PM

Microbiome Therapies for Food Allergy: Where Do We Go from Here?

Rima Rachid, MD

1:30 PM – 2:00 PM

Q&A | Panel Discussion

Moderators: Sarina Tanimoto, MD, MBA, Stephen Tilles, MD

2:00 PM – 2:15 PM

Break

2:15 PM – 3:15 PM

Pharmaceuticals in Development

- Intromune Therapeutics | William Berger, MD, MBA
- Alladapt Immunotherapeutics | Mei-Lun Wang, MD
- Stallergenes Greer | Anne-Marie Irani, MD
- Genentech | Ahmar Iqbal, MD
- DBV Technologies | Pharis Mohideen, MD

3:15 PM – 3:35 PM

Q&A | Panel Discussion

Moderator: Sarina Tanimoto, MD, MBA, Stephen Tilles, MD

Closing Remarks

3:35 PM – 3:45 PM

Closing Remarks and Adjourn

Stephen Tilles, MD



Daniel Adelman, MD

University of California, San Francisco

Dr. Adelman holds an academic appointment at the University of California, San Francisco as adjunct professor of Medicine, and is a fellow of the American Academy of Allergy, Asthma & Immunology, the Clinical Immunology Society, and the American College of Physicians.

Dr. Adelman trained in Internal Medicine and was a clinical and research fellow at UCLA in the Division of Clinical Immunology and Allergy; he completed a National Institutes of Health (NIH) / Public Health Service Tumor Immunology Fellowship. Dr. Adelman then took a position on the faculty at University of California, San Francisco, School of Medicine, where he was director of Clinical Allergy/Immunology in the Division of Allergy and Immunology, and director of the Outpatient Center for Clinical Research. He holds an AB degree in Biology from University of California, Berkeley and received his medical degree from the University of California, Davis.

For over 25 years, Dr. Adelman has been developing novel therapeutics in the biotechnology industry in the San Francisco Bay Area. Dr. Adelman was Chief Medical Officer at Aimmune Therapeutics where he was responsible for leading the development of Palforzia®, the first treatment for patients with food allergies approved by the U.S. Food and Drug Administration and the European Medicines Agency (FDA/EMA-approved). Prior to that he was Senior Vice President of Development and Chief Medical Officer at Alvine Pharmaceuticals Inc., a biotechnology company devoted to the development of a pharmaceutical treatment for celiac disease. Earlier in his career, Dr. Adelman was Senior Vice President, Development and Chief Medical Officer at Sunesis Pharmaceuticals, served in various roles at Pharmacyclics, including VP, Clinical Operations and Biometrics, and was a Clinical Scientist at Genentech where he led the early clinical development of two therapeutic monoclonal antibodies, Xolair® and Avastin®. Dr. Adelman has been involved in all stages of pharmaceutical drug development and is extensively published.



Aikaterini (Katherine) Anagnostou, MD, PhD
Baylor College of Medicine

Dr. Anagnostou is professor of Pediatrics at Baylor College of Medicine and Texas Children's Hospital. She serves as director of the Food Immunotherapy Program, director of the Food Challenge Program, and co-director of the Food Allergy Program. She is also lead for Adolescent Transition for Allergy.

Dr Anagnostou is passionate about investigating new and innovative treatments for food allergy. She has developed a strong interest in preventing and treating all forms of allergic disease and is committed to improving the quality of life of patients with allergies and their families.

Dr Anagnostou studied medicine at Aristotle University of Thessaloniki. She obtained her doctorate from the University of Cambridge in the United Kingdom. Her dissertation focused on two separate trials of peanut oral immunotherapy in children. Her research was published in The Lancet and received international recognition.



William Berger, MD, MBA
Intromune Therapeutics

Dr. Berger received his medical degree from the University of Cincinnati College of Medicine. He then completed an internship and residency program in pediatrics at the UCLA Medical Center. He pursued additional training at the National Jewish Hospital and Research Center where he served as a Fellow in Allergy and Immunology. Board certified in both pediatrics and allergy and immunology, Dr. Berger founded the Allergy and Asthma Associates of Southern California Medical Group in 1981 in Mission Viejo, CA, where he practiced both adult and pediatric allergy.

In 1995, Dr. Berger established the Southern California Research Center, focusing on respiratory and allergy clinical research projects. To further his educational goals, Dr. Berger received his master's degree in business administration from the Graduate School of Management of the University of California, Irvine. He held dual appointments as clinical professor at the College of Medicine, Department of Pediatrics, Division of Allergy and Immunology, and adjunct professor of Health Care Management in the Graduate School of Management at the University of California, Irvine.

Dr. Berger has served as president of the Orange County and California Societies of Allergy, Asthma, and Immunology. He has also been a member of the Joint Task Force on Practice Parameters, chair of the Managed Care Committee of the American College of Allergy, Asthma & Immunology, and chair of the Mission Hospital Institutional Review Board. Dr. Berger is a past president of the American College of Allergy, Asthma & Immunology, a professional organization that represents more than 6,000 allergy and asthma specialists throughout the United States and from many foreign countries. A former television medical correspondent for the Orange County Newschannel, Dr. Berger is the author of many academic papers and lay press articles in the field of allergy, asthma, and immunology, including the published book "Asthma for Dummies."



Mathew Greenhawt, MD, MBA, MSc
University of Colorado School of Medicine

Dr. Greenhawt is a professor in the Department of Pediatrics Section of Allergy and Immunology at Children's Hospital Colorado and the University of Colorado School of Medicine. Dr. Greenhawt earned his medical degree from Tufts University School of Medicine. He then completed his residency in pediatrics at Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia Presbyterian Medical Center and his fellowship in allergy/immunology at the University of Michigan. He also holds an MBA from Tufts University and a master's degree in health and healthcare policy from the University of Michigan, Rackham School of Graduate Studies. Dr. Greenhawt is board certified in pediatrics and allergy/immunology.

Dr Greenhawt's research interests include shared decision making, food allergy cost-effectiveness and comparative effectiveness research, food-allergic diseases health services research, primary/secondary prevention and treatment of food allergy, and food allergy public policy.

Dr Greenhawt has authored a number of peer-reviewed articles, abstracts, and book chapters. He is the senior associate editor for the Annals of Allergy, Asthma & Immunology, and a member of the Joint Task Force on Practice Parameters. Dr. Greenhawt is a member of many professional organizations, including the American Academy of Allergy, Asthma & Immunology (AAAAI), the American Academy of Pediatrics, the American College of Allergy, Asthma & Immunology, and the European Academy of Allergy and Clinical Immunology (EAACI). He is also involved with many committees, including the Brighton Collaboration Criteria Vaccine Anaphylaxis Case Definition 2.0 work group, and multiple AAAAI and EAACI committees.



Mike Holfinger, PhD
Alladapt Immunotherapeutics

Dr. Holfinger is currently the Chief Technical Officer at Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company focusing on the development of prescription therapeutics to treat IgE-mediated food allergy in mono- and multi-allergic individuals. He is responsible for all product development, analytical, manufacturing, and supply chain activities at Alladapt. Prior to joining Alladapt, Dr. Holfinger was Senior Vice President, Technical Operations at Aimmune Therapeutics where he led all product development and manufacturing activities to support clinical development and commercialization of Palforzia®, the first FDA/EMA-approved treatment for patients with food allergies.

Dr. Holfinger holds BS degrees in Applied Science and Chemistry from Miami University – Oxford and a PhD in Chemical Engineering from University of Wisconsin – Madison. Early in his career, he held product/process development and manufacturing roles in a number of large pharmaceutical companies and smaller biotech companies including Upjohn, Pharmacia, Pfizer, Affymax, Alexza, and Pliant Therapeutics.



Ahmar Iqbal, MBBS, MBA
Genentech

Dr. Iqbal is currently the Group Medical Director for Respiratory US Medical Affairs at Genentech. Among other things, he leads the scientists that work on omalizumab and pirfenidone.

One of the major projects that he is working on is the Genentech/Novartis collaboration with the NIH and the Consortium for Food Allergy Research on the project to assess the efficacy of omalizumab for food allergies.

During the three years prior to joining Genentech, Dr. Iqbal was the Global Medical Affairs Lead in GSK's Respiratory franchise overseeing medical affairs teams for respiratory products mainly in the area of chronic obstructive pulmonary disease.

Previously, he has worked at Pfizer Inc., where he held senior management positions in the Health Outcome Services Group and in Medical Affairs. While in the Health Outcomes Department, he led a staff of clinical researchers in developing clinical decision support software and in implementing clinical studies, both in the US and internationally. From 2007 to 2012, he was the Senior Medical Director for the Respiratory Medical Affairs Group at Pfizer working primarily on tiotropium.

Dr. Iqbal received his medical training in Pakistan and an MBA from Boston University. He practiced for a number of years as an internist and family physician. He has also had a career as a faculty member at an academic medical center and in the medical directors office in a US health plan. In addition, he has worked on quality-of-care initiatives and medical consensus building as a provider to the RAND Corporation prior to joining industry.



Anne-Marie Irani, MD
Virginia Commonwealth University

Dr. Irani is professor emerita of Pediatrics at the Children's Hospital of Richmond at Virginia Commonwealth University (VCU). She received her medical degree from the American University of Beirut in Lebanon and completed fellowships in allergy/immunology as well as pediatric rheumatology in New York, Boston and VCU in Richmond where she served as past chair of the Division of Pediatric Allergy, Immunology and Rheumatology, co-director of the Allergy Immunology Fellowship program, and professor of Pediatrics and Internal Medicine. In 2019, Dr Irani joined the pharmaceutical industry as a medical expert for GSK. From November 2020 until February 2023, she joined Aimmune Therapeutics as a Senior Medical Director where she led the global development of the toddler indication for Palforzia®, the first FDA/EMA-approved treatment for patients with food allergies.

During her scientific career, Dr. Irani authored or co-authored numerous peer-reviewed publications, and more than 20 reviews or book chapters. Her research interests included the development and biology of human mast cells. She also served the medical community on various boards and committees, including the editorial board of The Journal of Allergy and Clinical Immunology, the boards of directors of the American Academy of Allergy, Asthma & Immunology and the American Board of Allergy and Immunology, the executive committee of the Section on Allergy and Immunology of the American Academy of Pediatrics, and the secretary treasurer of the American Board of Medical Specialties. Currently, Dr Irani is a member of the Board of Trustees of INTEALTH, previously the Education Commission for Foreign Medical Graduates, and the Foundation for Advancement of International Medical Education and Research.



Jay Lieberman, MD
University of Tennessee

Dr. Lieberman is professor in the Department of Pediatrics at the University of Tennessee Health Science Center and a practicing physician at LeBonheur Children's Hospital.

Dr Lieberman currently serves as chair for the American College of Allergy, Asthma & Immunology food allergy committee, on the Board of Directors of the American Board of Allergy and Immunology, as co-chair of the Joint Task Force on Practice Parameters, and as an associate editor for the Annals of Allergy, Asthma & Immunology.

He completed his internal medicine residency at Washington University and Barnes Jewish Hospital in St. Louis, and later completed his allergy training at Mount Sinai Hospital in New York, where he was awarded the American Academy of Allergy, Asthma & Immunology (AAAAI)/Elliot and Roslyn Jaffe Third-Year Fellowship Food Allergy Research Award to take an extra year of fellowship training to research food allergies.



Pharis Mohideen, MD, MS
DBV Technologies

Dr. Mohideen serves as Chief Medical Officer and is a member of DBV's executive committee, responsible for continuing development efforts of the company's pipeline and bringing potentially innovative new treatments to patients, if approved. Dr. Mohideen brings nearly two decades of industry experience and a track record of multiple drug product approvals. Prior to joining DBV, Dr. Mohideen served as Chief Medical Officer for Millendo Therapeutics, Inc., Vice President of Clinical Development at Shionogi Inc., and other clinical and medical leadership roles with Novartis International AG and Bristol Myers-Squibb. Prior to joining the pharmaceutical industry, Dr. Mohideen was an attending physician and assistant professor of Medicine at the University of Hawaii, Department of Internal Medicine, and served as an investigator on multiple pharmaceutical-sponsored clinical trials.

Dr. Mohideen received his MD, MS in human physiology, and BA in biology from the University of Hawaii, as well as his MS in clinical investigation from Vanderbilt University.



S. Shahzad Mustafa, MD
Rochester Regional Health
University of Rochester School of Medicine and Dentistry

Dr. Mustafa is the chief of Allergy, Immunology, and Rheumatology at Rochester Regional Health, where he sees both pediatric and adult patients. Dr. Mustafa is also on faculty at the University of Rochester, where he is clinical associate professor of Medicine, and the clerkship director for the medical student elective in allergy/clinical immunology. In addition to teaching and seeing patients, Dr. Mustafa is also a lead investigator on multiple clinical research projects, with a special interest in quality-of-life considerations in food allergy and secondary immunodeficiency due to malignancy and chemotherapeutics.

Dr. Mustafa pursued his undergraduate studies at Johns Hopkins University and attended medical school at SUNY Buffalo. He then completed his internal medicine training at the University of Colorado and stayed in Denver to complete his fellowship training in allergy and clinical immunology at the University of Colorado, National Jewish Health, and Children's Hospital of Denver.



Anna Nowak-Wegrzyn, MD, PhD
NYU Grossman School of Medicine

Dr. Nowak-Wegrzyn is a professor of Pediatrics at the NYU Grossman School of Medicine, the director of the Pediatric Allergy and Immunology Division, Department of Pediatrics, the Hassenfeld Children's Hospital, New York, NY, and the director of the FARE Clinical Network Food Allergy Center of Distinction at NYU. Her research interests focus on egg and milk allergies, baked milk and baked egg diets, food-induced anaphylaxis in children, novel diagnostic and therapeutic approaches to food allergy (oral, sublingual and patch immunotherapy), oral tolerance development, and in particular food protein-induced enterocolitis syndrome (FPIES).

She has served as on the Board of Directors of the American Board of Allergy and Immunology (ABAI) since 2017. In 2022, she was elected to chair the ABAI board of directors. She serves as the chair of the Medical Advisory Board for the International FPIES Association and has led the international effort to write the first Consensus Guidelines for Diagnosis and Management of FPIES, published in 2017. She is associate editor for the Annals of Allergy, Asthma & Immunology, the official journal of the American College of Allergy, Asthma & Immunology. She completed her MD at Jagiellonian University and PhD at University of Warmia and Mazury.



Sung Poblete, PhD, RN
Food Allergy Research and Education (FARE)

Dr. Poblete is FARE's CEO, joining the organization in May 2022 from Stand Up To Cancer (SU2C) where she had served as Chief Executive Officer since 2011. She has an extensive and varied background, receiving BS and MS degrees, as well as a PhD in nursing, from Rutgers, The State University of New Jersey. She began her teaching career at Rutgers over 25 years ago and continues to serve as a visiting associate professor at their School of Nursing. In 2016, Sung was inducted into Rutgers Hall of Distinguished Alumni, joining a select group of more than 200 honorees across Rutgers' 256-year history who have devoted time and energy to the greater good of society.

Early in her career, Dr. Poblete held executive positions with a focus on patient outcomes and disease management. Notably, as Vice President of Clinical Operations for a subsidiary of Fresenius Medical Care North America, she developed and ran national chronic kidney disease management programs. As Executive Director of the Oxford Health Plans Foundation, she facilitated grants that furthered research and programs aimed at improving health care delivery.

The recipient of numerous high-level research funding grants from the Centers for Disease Control and Prevention, National Institutes of Health, National Science Foundation, and private foundations, Dr. Poblete also sits on the boards of several organizations, including the Osteosarcoma Institute, Apricity Health, and Proteus Ocean Group.



Ronald Rabin, MD

United States Food and Drug Administration

Dr. Rabin is Chief of the Laboratory of Immunobiochemistry (LIB), Center for Biologics Evaluation and Research, US Food and Drug Administration. As the Chief of LIB, Dr. Rabin supervises the reference reagent laboratory to ensure proper potency measurements of standardized allergen extracts and the evaluation of “chemistry, manufacturing and controls (CMC)” allergenic products that are in clinical studies or under consideration for licensure. Additionally, Dr. Rabin was the primary clinical reviewer for the first sublingual immunotherapy (SLIT) products approved for grass and ragweed allergies.

Dr. Rabin received his medical degree at the University of South Florida College of Medicine, completed his residency in Pediatrics at the University of Kentucky, and his fellowship in Allergy and Immunology at the National Institute of Allergy and Infectious Diseases.



Rima Rachid, MD

Harvard University

Dr. Rachid is the director of Allergen Immunotherapy and the co-director of the Food Allergy Program at Boston Children’s Hospital (BCH) and an associate professor of Pediatrics at Harvard Medical School. She is the principal investigator of the FARE Clinical Network Discovery Center at BCH. She leads multiple interventional and non-interventional clinical and translational research projects evaluating novel therapies for food allergy. She serves as the BCH scientific lead for the Children’s Hospital Pediatric Research Alliance (CHPRA). She also serves as the vice chair of the Food Allergy and Eosinophilic Disorders Interest Section at the American Academy of Allergy, Asthma & Immunology (AAAAI) and as member in the AAAAI Annual Meeting Program Committee. She has collaborated with her colleagues at BCH on pioneering the use of monoclonal anti-IgE therapy omalizumab as an adjunct therapy to oral immunotherapy (OIT) in patients with severe peanut allergy. The protocol was very successful, allowed for rapid and safe desensitization, and was adopted in other centers and trials.

Dr. Rachid is an expert in evaluating the microbiome and microbiome interventions in food allergy. Her studies showed that there is ongoing dysbiosis in children with food allergy and led to discoveries that small bacterial consortia can prevent or treat food allergy in highly allergic mice. The team also identified the immunological pathway through which the bacterial therapy induced tolerance, the results of which were published in the prestigious journal Nature Medicine.

Dr. Rachid has led the first trial in the world to evaluate the role of fecal microbiota transplantation (FMT) in food allergy. The results were very promising, which prompted the launching of a phase II trial evaluating the role of microbiota transplantation therapy (MTT)—a much more purified form of FMT containing <1% fecal material—in adolescents with peanut allergy. These cutting-edge studies will provide the impetus for larger studies evaluating the microbiome in food allergy, and ultimately the development of second-generation human probiotic therapies.

Dr. Rachid’s work has been published in cutting-edge journals including Nature Medicine, the New England Journal of Medicine, Immunity and The Journal of Allergy and Clinical Immunology. Dr. Rachid is a co-inventor on four patents targeting the treatment and prevention of food allergy and anaphylaxis.



Hugh Sampson, MD

Icahn School of Medicine at Mount Sinai

Dr. Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and director emeritus of the Jaffe Food Allergy Institute. Dr. Sampson's research interests have focused on food allergic disorders, and now include work on the pathogenesis of food-induced anaphylaxis, characterization of allergenic food proteins and their processing by the immune system, genetics of food allergy, development of novel diagnostic tests, and mechanisms of immunotherapeutic strategies for treating food allergies, including basic studies and clinical trials in oral, sublingual, and epicutaneous immunotherapy, and the potential use of biologics, such as anti-IgE and anti-cytokine monoclonal antibodies. His research is funded by a number of grants from the National Institutes of Health, including the recently funded Exposure to Vaginal Microbiome in C-section Infants at High-risk for Allergies – A Pilot Study. Dr. Sampson supervises one clinic/week in pediatric allergy and is involved in teaching fellows and residents. He is past president of the American Academy of Allergy, Asthma & Immunology, past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics, and a member of the National Academy of Medicine. He received his medical degree from University at Buffalo School of Medicine and completed his pediatric residency at Northwestern University and his allergy/immunology fellowship at Duke University.



Marcus Shaker, MD, MSc

Dartmouth Geisel School of Medicine

Dr. Shaker is a professor of Pediatrics and of Medicine at the Dartmouth Geisel School of Medicine, and a member of the AAAAI Board of Directors and AAAAI/ACAAI Joint Task Force on Practice Parameters. Dr. Shaker is also an associate editor of *Annals of Allergy, Asthma & Immunology* and an editorial board member of *The Journal of Allergy and Clinical Immunology: In Practice* and the *Journal of Food Allergy*. Dr. Shaker's research interests center around optimizing value-based care in allergy and clinical immunology.

Dr. Shaker attended medical school and completed his pediatrics residency at the University of Virginia, remaining in Charlottesville during his fellowship in allergy and immunology.



Sayantani (Tina) Sindher, MD
Stanford University

Dr. Sindher is a clinical associate professor in the Department of Medicine at Stanford University and is the director of the Clinical Translational Research Unit at the Sean N. Parker Center for Allergy and Asthma Research (SNP Center). She completed her pediatrics residency at Albert Einstein College of Medicine, Children's Hospital at Montefiore in Bronx, NY and her fellowship in Allergy and Immunology at Children's Hospital of Philadelphia, Philadelphia, PA.

Dr. Sindher divides her time between clinical research trials at the SNP Center and outpatient pediatric allergy/immunology at Lucille Packard Children's Hospital. She is the principal investigator of several clinical trials addressing atopic conditions including food allergy, atopic dermatitis, and asthma. Her present interests lie primarily in food allergy and eosinophilic esophagitis research involving strategies for prevention, diagnostics, and novel therapeutics.




Jonathan Spergel, MD, PhD
Children's Hospital of Philadelphia

Dr. Spergel is currently professor of Pediatrics and holds the Stuart Starr Chair of Pediatrics at the Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania. Dr. Spergel received his medical and graduate education at Mount Sinai School of Medicine and completed his pediatric residency at Yale-New Haven Hospital. His clinical and post-graduate training in allergy and immunology were completed at Children's Hospital, Harvard Medical School, Boston, MA.

Dr. Spergel is the principal investigator for the FARE Clinical Network Discovery Center at Children's Hospital of Philadelphia and the Data Coordinating Center for the FARE Clinical Network. He has been doing food research for the last 25 years and participated in both NIH and industry-related food allergy trials. He has published over 300 peer-reviewed publications in the field and is currently deputy editor for Annals of Allergy, Asthma & Immunology.

His research and clinical interests focus on all areas of food allergy including atopic march, prevention of food allergy, IgE-mediated food allergy, eosinophilic esophagitis, and food protein-induced enterocolitis syndrome.



Sarina Tanimoto, MD, MBA
ARS Pharma

Dr. Tanimoto is a co-founder of ARS Pharma and has served as Chief Medical Officer since 2018. Prior to joining ARS Pharma, she served as Chief Medical Officer of Pacific-Link Regulatory Consulting and Research, Inc., a medicinal product development consultancy, where she supported multiple programs from Phase 1 to Phase 3 clinical trials in various therapeutic areas, including several intranasal products. Prior to Pacific-Link Regulatory Consulting and Research, Inc., Dr. Tanimoto held roles in clinical and business development during her tenure at AnGes Inc., a biopharmaceutical company, and also served as a clinical scientist at Roche, a research healthcare company, where she was involved in global clinical development.

Dr. Tanimoto earned a medical degree from University of Toyama, followed by internal medicine training at the National Center for Global Health and Medicine in Tokyo. She holds an MBA from McGill University.



Stephen Tilles, MD
Aimmune Therapeutics

Dr. Tilles is Global Head of Medical Affairs, Allergy at Aimmune Therapeutics, a Nestlé Health Science Company. In addition to this role, he currently serves as clinical professor of Medicine at the University of Washington and is a fellow of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology (ACAAI).

His previous roles include president of the ACAAI, assistant professor of Medicine and Pediatrics and director of the Allergy and Asthma Clinic at Oregon Health Sciences University (OHSU), and service on both the Joint Task Force for Practice Parameters and the American Board of Allergy and Immunology.

Dr. Tilles was previously a partner at the Northwest Asthma and Allergy Clinic in Seattle, WA and executive director of ASTHMA Inc, a non-profit clinical research center. He served as principal investigator for more than 140 clinical trials involving treatments for asthma, allergic rhinitis, urticaria and atopic dermatitis, as well as 13 trials evaluating treatments for food allergy. He has authored more than 100 papers in peer-reviewed publications.

His educational background includes a bachelor's degree from Harvard College, a medical degree from the University of California San Diego School of Medicine, internal medicine residency training at OHSU, and fellowship training in allergy and immunology at the National Jewish Center for Immunology and Respiratory Medicine.



Alkis Togias, MD
National Institutes of Health (NIH)

Dr. Togias is the chief of the Allergy, Asthma and Airway Biology Branch at the Division of Allergy, Immunology and Transplantation of the National Institute of Allergy and Infectious Diseases (NIAID), NIH. His responsibility is to supervise the stewardship of all NIAID-funded grants and programs, as well as the scientific research initiatives in allergic diseases, asthma, and inflammatory upper airway conditions. This includes the NIAID-funded clinical networks (Childhood Asthma in Urban Settings [CAUSE], Consortium for Food Allergy Research [CoFAR], Atopic Dermatitis Research Network [ADRN], Asthma and Allergic Diseases Cooperative Research Centers [AADCRC], and the allergy projects of the Immune Tolerance Network [ITN]), as well as investigator-initiated clinical trials and investigator-initiated research project grants. Dr. Togias also co-directs the NIAID-funded Human Immunology Project Consortium (HIPC) and is a project scientist in the Airways Workgroup of the NIH-funded Environmental Influences on Child Health Outcomes (ECHO) initiative.

Dr. Togias earned his medical degree at the National and Kapodistrian University of Athens, Greece and received his post-doctoral research and clinical training in medicine and then in allergy and clinical immunology at The Johns Hopkins Hospital and Johns Hopkins University. He was on faculty at Johns Hopkins University from 1989 to 2006, when he joined the NIH.



Anubha Tripathi, MD
United States Food and Drug Administration

Dr. Tripathi is a physician sub-specialized in Allergy and Clinical Immunology and serves as a clinical reviewer in the Clinical Review Branch of the Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research for the U.S. Food and Drug Administration. She conducts review of the clinical development programs for investigational allergenic and vaccine products for various indications. Dr. Tripathi received her medical degree from the Medical College of Virginia in Richmond, Virginia and completed her medical residency training in internal medicine at Tufts Medical Center in Boston, Massachusetts. She completed her allergy and clinical immunology fellowship at the University of Virginia Health System in the Division of Allergy and Clinical Immunology where she also served on faculty as assistant professor of Medicine. She has served as an attending physician in internal medicine and in allergy and clinical immunology in both academic hospital settings and private hospital and medical practice settings. Her research interests have focused on food allergy and eosinophilic esophagitis. She has run clinical trials and research studies and has authored several publications in these areas in books and medical journals including The Journal of Allergy and Clinical Immunology and The Journal of Allergy and Clinical Immunology: In Practice. She has also presented her research in these areas at scientific meetings of the American Academy of Asthma, Allergy & Immunology, the American College of Asthma, Allergy & Immunology, the European Academy of Allergy and Clinical Immunology, and various other organizations.



Yamini Vikas Virkud, MD, MA, MPH
University of North Carolina

Dr. Virkud is a pediatric allergist/immunologist and assistant professor at UNC-Chapel Hill. She is also adjunct faculty at Massachusetts General Hospital, Boston, MA. She completed her medical training at Washington University in St. Louis, and concurrently obtained a master's degree in Biology and Biomedical Sciences at Washington University. She completed her residency in pediatrics at St. Louis Children's Hospital. She trained at Duke University for her fellowship in allergy and immunology, where she researched under the mentorship of Dr. Wesley Burks, exploring the safety of peanut oral immunotherapy for food allergy. During this time, she also completed a clinical research fellowship at Duke Clinical Research Institute and a Master of Public Health in Biostatistics at the University of North Carolina-Chapel Hill. From 2014 to 2021, she was a faculty member at Massachusetts General Hospital and Harvard Medical School, and became the director of Biostatistics and Data Management core of the MGH Food Allergy Center. In 2021, she joined the UNC Food Allergy Initiative. Her research focuses on the phenotyping of different patients with food allergy and understanding the mechanisms of investigational therapies for food allergy.



Mei-Lun Wang, MD
Alladapt Immunotherapeutics

Dr. Wang is Vice President and Head of Clinical Development at Alladapt Immunotherapeutics, where she oversees the strategic development of ADP101, a multi-food oral immunotherapy (OIT) for the treatment of patients with food allergy. Dr. Wang has 10 years of experience in drug development, and previously led early and late clinical development programs in a variety of immunoinflammatory disease areas including inflammatory bowel disease (IBD), psoriasis, rheumatoid arthritis, and systemic lupus erythematosus (SLE) at GlaxoSmithKline (GSK) and Janssen.

Dr. Wang earned her undergraduate degree from Cornell University and her medical degree from the Perelman School of Medicine at the University of Pennsylvania. She completed her pediatric residency and chief residency at the University of Washington, Seattle Children's Hospital. After completing her fellowship in pediatric gastroenterology at the Children's Hospital of Philadelphia (CHOP), she was an attending physician in pediatric GI at CHOP, and assistant professor of Pediatrics at the Perelman School of Medicine. Prior to joining the pharmaceutical industry, Dr. Wang was an academic physician-scientist who established a basic-translational program in eosinophilic esophagitis (EoE) and was a founding member of the joint Penn/CHOP EoE Research Group, established as part of the Joint Penn/CHOP Center for Digestive Diseases to foster collaboration in basic, clinical, and translational EoE research.



FARE®
FoodAllergy.org